Phacilitate Leaders World

Sponsors & Exhibitors

BIA Separations

BIA Separations is the leading developer and manufacturer of CIM® (Convective Interaction Media) monolithic chromatographic columns for production, purification, and analytics of large biomolecules. Our highly skilled team has more than 2 decades of accumulated knowledge in Downstream Processing and HPLC Analytics.

CIM® monolithic columns stand for elaborate design providing high efficiency, high speed, and high yield in downstream processing of viruses, VLPs, phages, pDNA, and large proteins. CIM® monolithic columns are distinguished for their flow independent performance, resulting in fast separation, concentration, purification, removal and analytics.

Our mission is to develop and produce CIM® monolithic columns of the highest quality, and to provide superior method development services for Purification and HPLC Analytics of biopharmaceuticals.

Visit Website
View all Sponsors & Exhibitors
Loading
Testimonials
  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Anne-Virginie Eggimann
    bluebird bio
  • Great program, great people, great venue.
    Klaus Kühlcke
    EUFETS GmbH
  • Dynamic, interesting and highly interactive event that promotes exchange and networking in highly specialized field of gene therapy.
    Nathalie Clement
    Powell Gene Therapy Center, University of Florida
  • Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field.
    Dr James Trager
    Dendreon
  • It was all business. I’ve never been to an event where over 80% of the conversations I had were constructive to my business objectives.
    Kurt Gielen
    Chemelot Campus B.V.
  • Great way to expand network with global experts in cell and gene therapy who are facing similar challenges.
    Steven Goodman
    GSK